Clomiphene alters estrogen signaling and thus potentially affects lipid metabolism and bone status. The editors found out what is known about the effect of the drug on cholesterol and triglycerides, why estradiol is important for bones in men, and where the data ends and the assumptions begin.
Why lipids and bones are important for SERMs
Estrogens affect not only the reproductive system. They are involved in the regulation of lipoprotein metabolism in the liver and in the maintenance of bone mineral density in both women and men. Therefore, any drug that alters estrogen signaling has the potential to affect the lipid profile and bone tissue.
Clomiphene belongs to the class of selective estrogen receptor modulators. The key word here is "selective": SERMs can act oppositely in different tissues. Tamoxifen, for example, blocks receptors in breast tissue, but partially activates them in bone and liver. Raloxifene was created precisely on the basis of a positive effect on bones in postmenopausal women.
With regard to clomiphene, the situation is more complicated: it has been studied primarily as a means of inducing ovulation with short courses, so the long-term metabolic effects are much less well studied. However, the use in men, which can last for years, makes these questions more and more urgent.
An additional factor — in men, clomiphene increases the levels of both testosterone and estradiol. Therefore, its total effect on lipids and bones is determined not only by the molecule's own effect on receptors, but also by a change in the hormonal background in general.
Clomiphene and lipid profile: what is known
There are few systematic randomized trials specifically addressing the effects of clomiphene on lipids in men. Retrospective studies from urological centers describing long-term use generally did not report clinically significant adverse changes in total cholesterol or low-density lipoproteins, but lipid profiles were not always assessed by a single method.
In terms of mechanism, there are several possible effects. The partial estrogenic effect of SERMs in the liver, characteristic of tamoxifen and raloxifene, is associated with a decrease in LDL. At the same time, increasing testosterone levels within the physiological range usually has a moderate effect on lipids, in contrast to supraphysiological doses of androgens, which significantly lower high-density lipoproteins.
Triglycerides deserve special attention. Estrogenic effects on the liver can increase the synthesis of triglycerides, and isolated clinical cases of pronounced hypertriglyceridemia on the background of clomiphene have been described in the medical literature, in particular in women with initial disorders of lipid metabolism. This is rare, but it is important for people with familial hypertriglyceridemia.
In a practical sense, this means that for people with known disorders of lipid metabolism, the doctor can prescribe control of the lipid profile before and during therapy. A typical set of indicators is shown below.
- total cholesterol;
- low-density lipoprotein (LDL);
- high-density lipoproteins (HDL);
- triglycerides;
- if needed — apolipoprotein B or lipoprotein(a) to clarify cardiovascular risk.
Bone tissue: the role of estradiol in men
Estradiol formed from testosterone is important for male bone health as well as testosterone itself. Finkelstein and colleagues directly examined bone turnover and bone density during controlled gonadal steroid suppression and aromatase inhibition in their 2016 Journal of Clinical Investigation study. Its results support an important role for estrogen deficiency in male bone loss.
This has an important consequence for clomiphene. Since the drug increases the level of testosterone, and with it, estradiol, its systemic effect on bones should theoretically be neutral or favorable. This distinguishes it from aromatase inhibitors, which with long-term use reduce estradiol and can negatively affect bone mineral density.
There are few direct data on the effect of clomiphene on bone tissue in men. There are no large studies evaluating fractures as an end point. Therefore, the claim of "bone protection" by clomiphene is a hypothesis based on physiology rather than a proven clinical outcome.
In women, clomiphene is used in short courses, so the effect on bones in them was practically not studied. Class SERM data, particularly the results of the MORE study with raloxifene, cannot be automatically transferred to clomiphene: the molecules have different tissue selectivities.
Comparison with other means of influence on the hormonal axis
To evaluate the place of clomiphene, it is useful to compare it with other approaches that alter the hormonal background in men. The metabolic consequences here depend on what happens to estradiol and how high androgen levels become.
| Intervention | Estradiol | Expected effect on bone | Effect on HDL |
|---|---|---|---|
| Clomiphene | Increases | Likely neutral or favorable (little data) | There are few data |
| Aromatase inhibitors (long-term) | Decreases | Possible loss of density | Possible decrease |
| Testosterone in physiological doses | Increases | Favorable for hypogonadism | Moderate impact |
| Supraphysiological doses of androgens | Depends on the drug | Ambiguous | Marked decrease |
The table shows that clomiphene has theoretical advantages over long-term aromatase blockade with respect to bone. However, in the absence of direct data, these preferences should be formulated with caution.
It is also important that the metabolic profile depends on the initial state of the person: body weight, lifestyle, genetics, concomitant diseases. For a person with obesity and metabolic syndrome, lipid changes may have a completely different clinical significance than for a healthy young man.
Finally, in a sports context, clomiphene is often combined with other substances, primarily anabolic steroids. In this case, lipid changes are primarily determined by androgens, and the contribution of clomiphene is almost impossible to estimate.
Monitoring and practical recommendations
If a doctor prescribes clomiphene long-term, monitoring usually includes not only hormones, but also general health indicators. A lipid panel is a readily available blood test that allows you to detect unwanted changes in time, especially in people with cardiovascular risk factors.
For bone, routine bone densitometry is usually not required in the setting of clomiphene. However, in men with long-term hypogonadism, low body weight, or a history of fractures, the doctor may recommend a bone mineral density assessment regardless of the treatment method chosen.
The basic factors of bone health and lipid metabolism work independently of drugs: adequate calcium and protein intake, normal vitamin D levels, strength training, smoking cessation, and alcohol restriction. No drug can compensate for their absence.
People who have already been diagnosed with hypertriglyceridemia should be especially careful. For them, any estrogen-active intervention is a reason for more frequent control of tests and discussion with the doctor about the ratio of benefit and risk.
Editorial conclusions
The effect of clomiphene on the lipid profile and bone tissue is less well studied than its hormonal effects. Available retrospective data do not indicate significant adverse changes in most men, but cannot completely exclude them.
Regarding bones, physiology shows in favor of clomiphene: it increases estradiol, which is important for bone tissue in men. However, this is a theoretical consideration, not confirmed by studies with fractures.
Regarding lipids, the most attention should be paid to triglycerides, especially in people with initial disorders of lipid metabolism. Analysis control and medical supervision remain mandatory.
For a deeper understanding of the topic, we advise you to read our articles on the side effects of clomiphene, on contraindications and interactions of the drug, as well as on the effect of enclomiphene on the lipid profile and bone tissue.
References
- Clomid (clomiphene citrate tablets USP). Prescribing information. U.S. Food and Drug Administration.
- Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011â1022.
- Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637â645.
- Krzastek SC, Sharma D, Abdullah N, et al. Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. J Urol. 2019;202(5):1029â1035.
- Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int. 2012;110(10):1524â1528.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715â1744.
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423â432.
